An observational study in Atopic Dermatitis, sponsored by Swiss Society of Dermatology and Venereology. Recruiting at 10 sites in Switzerland. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Swiss Society of Dermatology and Venereology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Dermatitis, Atopic with a site in Switzerland — 3 open to participants now, 5 under way, none of them phase 3. Dermatitis, Atopic · Switzerland.
Among the 31 studies in Dermatitis, Atopic with a site in Switzerland, this one is one of 4 that started in 2022, is one of 6 observational ones, and was the 25th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 31 studies in Dermatitis, Atopic with a site in Switzerland are open now. Recruiting first, the newest first:
Julia Tatjana Maul · Sites in Switzerland
Ages 14+
University of Zurich · Sites in Switzerland
Ages 1–85 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 10 · Phase 4 6
First in 2004; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 226 across the 23 interventional studies, 937 across the 6 observational. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 31 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Swiss Society of Dermatology and Venereology as lead sponsor.
Swiss Society of Dermatology and Venereology has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
1 of the studies in Dermatitis, Atopic with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06906497Johann E Gudjonsson MD PhDLebrikizumab in Moderate-to-severe Atopic Dermatitis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Dermatitis, Atopic with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As structured and detailed data on the management of AD, a common chronic inflammatory skin disease which has a high impact on patients' quality of life and socioeconomic burden, are not available in Switzerland, the planned registry will overcome this gap. It will provide data on the medical care of patients with AD for health care research and allow to study the efficacy and safety of approved and available therapies for AD in daily life.
A prospective, non-interventional, national multicenter study in patients with moderate-to-severe AD. According to the availability of approved systemic drugs for the treatment of AD, the study will include children ≥12 years, adolescents and adult patients.
The general goal of the AD registry TREATswitzerland is to provide the scientific community with a disease-oriented prospective cohort of patients suffering from moderate-to-severe AD.
The primary objective of the AD registry is the documentation of medical care given to patients with moderate-to-severe AD in order to assess the appropriateness of care.
Further objectives of the AD registry are:
The study procedures include:
The criteria were revised on the registry on Nov 17, 2026. See what changed
The study aims at including 700 patients with moderate to severe atopic dermatitis in the registry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluation of the type of systemic therapy used in patients with moderate-to-severe atopic dermatitis
assess medical substances given systemically to treat AD
Time frame: 24 months
assessment of patients demographic data
assess sex (male, female), age (years)
Time frame: 24 months
assessment of past treatment and current treatment
assess specific medical substances (name, dosage, duration of therapy, clinical effects, adverse effects)
Time frame: 24 months
assessment of concomitant topical therapy for AD and concomitant treatment
describe medical substances given for AD skin therapy (e.g. topical corticosteroids) and topical calcineurin inhibitors), and medical substances given for concomitant diseases
Time frame: 24 months
assessment of past and current comorbidities
describe diseases
Time frame: 24 months
change in subjective and objective SCORAD (SCORing Atopic Dermatitis)
outcome measure for disease severity
Time frame: 24 months
change in EASI (Eczema Area and Severity Index)
Investigator-assessed outcome measure for disease severity
Time frame: 24 months
change in DLQI (Dermatology Life Quality Index)
Patient-reported outcome measure for skin-related quality of life
Time frame: 24 months
change in POEM (Patient Oriented Eczema Measure)
Patient-reported outcome measure for atopic eczema severity
Time frame: 24 months
change in RECAP (Recap of atopic eczema)
Patient-reported outcome measure to capture eczema control
Time frame: 24 months
Started Jun 2022 (actual). Primary completion is estimated for May 2032, 119 months after the start.
Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 119 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.